The European Association of Urology guidelines on prostate cancer state that cryotherapy is a true therapeutic alternative for patients with clinically localized prostate cancer. The aim of this paper is to establish a uniform practice for performing prostate cryoablation. A collaboration has been set up among five European centres with experience in almost 1000 prostate cancer patients on the use of cryotherapy. The present recommendations were developed through sharing of experience and thorough discussions within the group. This first paper from the group establishes the technical recommendations for use of prostate cryotherapy.
Introduction
Cryotherapy has been performed in Europe for over 50 years. The European Association of Urology guidelines on prostate cancer state that cryotherapy is a true therapeutic alternative for patients with clinically localized prostate cancer. 1 The American Association of Urology recently made an announcement of a best practice statement confirming cryotherapy as a valid treatment option for both primary and recurrent localized prostate cancer. 2 In 2005 in the UK, the National Institute of Clinical Excellence approved the use of cryotherapy for patients with prostate cancer, both as a primary treatment and as salvage treatment after radiotherapy or hormone therapy. 3, 4 National Institute of Clinical Excellence clinical guidelines on prostate cancer released in February 2008 reversed this decision suggesting that the treatment should be used in the setting of clinical trials. Ongoing debate has resulted in a further revision to allow UK physicians to collect data on patients treated locally for funding requirements.
Cryotherapy causes cell death through two principle mechanisms. 5 First, as the temperature falls, extracellular ice crystallizes causing movement of water from the intracellular to the extracellular environment after an osmotic gradient. As the temperature continues to fall, intracellular ice crystals form, causing direct damage to the intracellular organelle system and the cell membrane. The second mechanism is platelet aggregation and microthrombus formation in small blood vessels, which leads to ischaemic change in the tissue area supplied by the affected blood vessels. These changes lead to coagulative necrosis and cause a well demarcated lesion as can be seen in Figure 1 . In addition, severe temperature changes and ischaemic change induce apoptosis in cells at the periphery of the cryolesion. 6 The effectiveness of the cellular destruction depends on rapid freezing, 7 the lowest temperature reached and slow thawing. This is generally achieved through two freeze-thaw cycles to a target temperature of À40 1C. 5 Cryoablation of prostate cancer first took place in 1968 using probes cooled by liquid nitrogen in a closed system. 8 The early technique was associated with considerable complications, such as rectorurethral fistulas, urethral sloughing and urinary incontinence. With the introduction of transrectal ultrasound (TRUS) guidance and the urethral warming catheter, improved results were achieved. The subsequent development of third generation cryotherapy using ultra-thin 17-gauge needles with echogenic tips has allowed highly controlled and accurate delivery of the treatment. The current system uses high pressure argon and helium gas for freezing and warming, respectively. The temperature change is governed by the Joule-Thompson effect, whereby high pressure gases, when forced though a very small opening into a low pressure area (within the tip of the CryoNeedle), undergo specific temperature changes. This allows the freezing and subsequent thawing of the prostate using the same needle. During the treatment, the temperature in different areas of the prostate is monitored in real time by means of interstitial thermosensors. The 17-gauge needles are placed under TRUS guidance through the skin of the perineum using a brachytherapy-like template without the need for tract dilatation and with minimal trauma to the patient. As the gas is delivered through the specialized needles, it cools the prostate tissue rapidly to the target temperature of -40 1C. The ice ball is clearly visible on TRUS as it forms and is monitored continuously throughout the procedure. The use of urethral warmer reduces the incidence of urethral sloughing.
A collaboration has been enacted among five European centres with experience in almost 1000 prostate cancer patients treated with cryotherapy. The procedure described here relates to the SeedNet equipment (Galil Inc.). The aims of the group are to establish a uniform practice for performing prostate cryoablation and to develop a prospective European database on long-term outcomes with this therapy. This first paper from the group reports on the second meeting of the group establishing the technical recommendations for prostate cryotherapy; subsequent publications will detail outcomes, including efficacy and safety.
Equipment

Work station
The computerized workstation that is used allows data input, procedure selection and a constant monitoring of system performance (Figure 2a ). It includes a patented Plug and Freeze technology. The screen on the workstation is operated by touch pad control, whereas the CryoNeedle manifold is located at the side, which supplies gas to the individual needles. The five integrated temperature sensors are also connected here (Figure 2b ). Up to 25 17-gauge needles in 5 groups can be used.
CryoNeedle
The patented 17-gauge (1.47 mm) needle technology produces precise and accurate ice balls (Figure 2c ). The needle shaft has 0.5 and 1 cm markings indicating distance from the tip and the thin grip optimizes handling and manoeuvrability during needle insertion. The sharp tip of each needle allows direct percutaneous insertion.
Staging of the disease
Cryotherapy with the SeedNet system is considered as a curative procedure for patients with a primary cancer of stage T1-T3. Patients with any Gleason score who are not suitable for radical prostatectomy can also be treated with cryotherapy. Recommendations for staging of prostate cancer before cryotherapy are similar to those used in other curative treatments and include T-staging through digital rectal examination and TRUS imaging, which will also establish the size of the prostate. A biopsy proven adenocarcinoma with Gleason grading is a prerequisite for treatment. Prostate-specific antigen (PSA) should be measured and a bone scan performed. Retroperitoneal lymph node dissection should be conducted or magnetic resonance imaging can be performed to detect nodal involvement if the PSA level is X15 ng ml -1 . 9 The distance from the apex of the prostate to the bladder neck should be measured. The size and length of the prostate must be taken into consideration when deciding needle selection. Generally, smaller and shorter prostates (o3.5 cm) can be treated with SeedNet CryoNeedles, whereas for larger (60-70 g) and longer prostates (X3.5 cm), IceRod needles might be used.
Salvage therapy
For patients who have failed primary external beam radiotherapy or brachytherapy, a positive prostate biopsy and lack of evidence of metastases on bone scan need to be established before treatment. Cryotherapy can also be used in patients failing primary hormonal therapy provided the cancer is still localized. In specific cases, patients failing radical prostatectomy can be considered for focal cryoablation if there is biopsy proven prostate cancer and a detectable lesion on TRUS. Cryotherapy as salvage therapy after any kind of radiotherapy is contraindicated in patients with active rectal bleeding, in patients with a history of fistula formation after radiotherapy and those with rectal ulceration. An interval of 2 years is recommended between radiotherapy and salvage cryotherapy to allow the late effects of radiation treatment to become apparent.
10,11
Pre-operative patient preparation
The patient should undergo a standard pre-operative assessment. Digital rectal examination should be carried out and an International Prostate Symptom Score and PSA level determined. Pre-treatment TRUS is recommended to assess the horizontal length, width and height of the prostate, as well as its shape and its relation to the pelvic bones. A liquid diet and a laxative should be given as standard in any large bowel procedure. The anus, Cryoablation of the prostate S Cytron et al perineum, scrotum, penis and the suprapubic areas are shaved before the procedure. All anticoagulative drugs (including aspirin) should be discontinued before cryotherapy or substituted with heparin after consultation with an angiologist or cardiologist. The patient should be informed of the potential side effects associated with the procedure as part of obtaining written informed consent.
Patient preparation in the theatre
Prophylactic antibiotics should be administered perioperatively. Cryotherapy is usually performed under general anaesthesia to assure that the patient does not move during the procedure. Alternatively, the procedure may be performed under spinal anaesthesia with sedation. Before insertion, all CryoNeedles should be tested for function. This entails observing the formation of an ice ball followed by thawing of that ice ball at the tip of each needle, dipped in a bowl of sterile normal saline, using the test run feature of cryotherapy machine ( Figure 3 ). The patient should be placed in the lithotomy position, with the hip at a 901 angle to prevent pelvic rotation; the leg supports should be adequately padded. Drapes should expose the anus, perineum, scrotum and penis, and the suprapubic area. Cystoscopy is performed to rule out any concomitant urological problems and to assess the urethral prostate, the proximity of the ureteric orifices to the prostate and to examine the bladder. A suprapubic catheter may be inserted at this time point. The tube draped on the patient allows some fluid to Cryoablation of the prostate S Cytron et al accumulate in the bladder, thus facilitating visualization of the bladder neck on ultrasound. A volume of 200-300 ml of urine may be left in the bladder during the procedure to protect the bladder wall. Therefore, the suprapublic catheter is clamped during the procedure and overflow is allowed through the warming catheter.
A long, stiff guide wire is inserted and left in place secured by a mosquito/straight clip when the cystoscope is withdrawn. An in-dwelling Foley catheter with a 10 ml balloon may further improve visualization of the urethra and bladder neck when placing the CryoNeedles. The scrotum should then be elevated using tape or an elevating suture to expose the perineum.
Ultrasound assessment of the prostate
The ultrasound equipment must have a transrectal probe with biplanar orthogonal array to assure optimal monitoring of the ice ball in both transverse and longitudinal planes during the procedure. The use of an inflatable rectal stand off (Brachyballon) for the TRUS probe is recommended to enhance echogenicity of the prostate gland and to facilitate the accommodation of the prostate image within the grid overlay on the ultrasound monitor. The probe may be inserted into the rectum to decide the optimal angle before it is mounted in the cradle. All dials and settings on the stepper are checked to make sure that they are in the neutral/mid position. The stand holding the stepper is fixed in position and the ultrasound probe mounted in the cradle (Figure 4) . With the probe inserted into the rectum, the pre-operative prostate measurements are checked in the transverse and longitudinal views and landmarks are re-defined. Prostate measurements are repeated: the maximum height and widest transverse diameter in the transverse view and the total length in the longitudinal view are recorded. The whole gland should be visualized by scanning from the base to the apex in the transverse view. The widest transverse section should be identified and its distance from the bladder neck recorded. This distance corresponds to the distance required to push the CryoNeedles past the widest transverse view, so that they are positioned approximately at the prostate base. The cryotherapy template is placed on its holder above the ultrasound probe on the stand in close proximity to the perineum. The widest transverse view image is overlaid with the template image on the ultrasound monitor by pressing the appropriate button on the ultrasound control panel.
Insertion of the SeedNet CryoNeedles
The operator's gloves should be changed before insertion of the CryoNeedles through the cryotherapy template Depending on the size of the prostate, between 12 and 15 CryoNeedles are placed in three to four rows, with each row containing one to five CryoNeedles, from the anterior to the posterior aspect (Figure 6a ). Row one is inserted in the anterior aspect and the co-ordinates and the number of CryoNeedles subsequently used are noted on the computer screen of the cryotherapy machine. The placement of the most posterior row of CryoNeedles is extremely important and a minimum of 1 cm should be present between the centrally placed posterior CryoNeedles and the rectal wall. Two needles may be placed just anterior to or in the rectal wall for active protection of the structure (Figure 6b ). The needles can be warmed with helium if the temperature in the rectum falls below acceptable ranges in reference to the location of the temperature sensor, depending on the progression rate of the ice front. 12 At least two thermosensor probes should be inserted using the same technique. These probes do not need to be tested in water before use, but they must be checked for function after insertion by observing registration of the body temperature. The first thermosensor is inserted into the prostate parenchyma, ideally in a position in which the CryoNeedles are less densely positioned and at least 1 cm from the warming catheter. This sensor will monitor adequate freezing of the prostate tissue. The second thermosensor is inserted in the anterior rectal wall or in the Denonvilliers' fascia to enable the precise monitoring of the rectal wall temperature and to commence active protection of the rectal wall if needed. Up to three more thermosensors can be inserted into any area in which precise temperature registration is desired, such as a known focus of the disease, for example the neurovascular bundles or the urethral sphincter. Before freezing, flexible cystoscopy is performed to ensure that the CryoNeedles are not perforating the urethra or the bladder. Fine tuning of the needle position and proximal depth is made with real-time TRUS monitoring.
Placement of the urethral warmer
The bladder should be partially filled before starting the prostate warming procedure and the suprapubic catheter clamped off. The urethral warming catheter is inserted over the guide wire and the urethral warmer pump started to ensure that the fluid circuit is functioning correctly. The warmer fluid temperature is set at 43 1C before the first freeze cycle is initiated.
Freeze-thaw cycles
If an inflatable rectal standoff is used, the water should be withdrawn before the first freeze cycle to expand the space between the prostate and the rectum and to avoid pressure from the ultrasound probe on the rectal wall. Two freeze-thaw cycles are performed under real-time TRUS guidance and direct temperature monitoring. Close attention must be given to the size and position of the ice ball in the transverse and longitudinal position with respect to the rectum. Freezing is started on row 1, the most anterior. As the ultrasound blackout, which starts as the ice starts to form, is identified, row 2 freezing commences and then subsequent rows are activated. A minimum temperature of -40 1C in the prostate is desirable, but temperatures of lower than À30 1C are acceptable. The freezing time usually takes about 10 min and the entire cycle must not be 412-15 min. Actual temperature is controlled using the thermosensors and the software provided on the cryosurgery delivery unit. Duration of gas flow can also be reduced or increased in a percentage fashion as required to control the procedure. All prostatic images should be scanned and checked continuously in both transverse and longitudinal view to check for the ice ball approaching the rectum. Active thawing of the rectal wall protection needles may be started as a safety Cryoablation of the prostate S Cytron et al measure if there is concern about the temperature at or ice-visualized propagating into the rectal wall.
After the completion of a freeze cycle with adequate ice ball formation, the prostate is allowed to thaw. This can be accomplished in two ways: passive and active thawing. During passive thawing, the freezing is turned off until a temperature 'plateau' appears. The latter is defined as no rise in temperature in a 30-s period. It is, however, sometimes desirable to give active thawing for a minute immediately after the freezing cycle is stopped to limit unwanted expansion of the ice ball. Otherwise, active thawing is started once the temperature sensors in the treated zone rise above 0 1C or are at plateau and it commences for 1 min in all rows, followed by 1 min of passive thawing. This process is repeated until the temperature is above 5 1C or rising continuously. After 5 or 6 min, the prostate becomes visible on ultrasound and a second freeze cycle can be started. The interval between freezing cycles may take up to 10-12 min.
For prostates longer than 3.5 cm, the CryoNeedles will need to be retracted to cover the remaining distance of the prostate from the periphery of the ice ball to the apex in a process called the 'pull-back procedure'. The distance is double checked on ultrasound in longitudinal and transverse views and then two further freeze-thaw cycles performed. If the ice ball extends 40.5 cm from the apical prostate capsule and full coverage of the prostate is visualized on ultrasound, then no pull back is necessary. The recent introduction of IceRods has made the pull-back procedure not necessary.
Protective measures
During cryoablation of the prostate, rectal temperatures should be kept above 0 1C. It is, however, important to be aware of the position of the thermosensor. If this is too close to the prostate, falsely low temperatures may be registered. The external urethral sphincter temperature should be maintained at over 15 1C. If the ice ball touches or extends too far into the rectal wall, the rectal warming needles can be activated and the intensity of freezing can be controlled by decreasing the duration of gas flow in the posterior rows to increase the temperature as necessary. Alternatively, any row of freezing CryoNeedles can be linked to a pre-set designated temperature sensor, which controls the freezing temperature in the specified area. When this auto freeze feature of the machine is used, continuous monitoring by ultrasound is still mandatory. Irrigation with warm water prevents ice formation on the needles at skin level. Colour doppler can be used to assess blood flow within the rectal wall and surrounding sensitive structures, but detection of blood flow is no guarantee that a freeze injury will not occur.
Post-operative procedures
At the end of the second thaw cycle, when the temperature in the prostate has reached at least 5 1C, the CryoNeedles are removed and disposed of in an appropriate manner. Pressure is applied to the perineum Cryoablation of the prostate S Cytron et al for 5 min or until the bleeding stops and then a dressing is placed on the perineum and the suprapubic puncture site. The urethral warmer is left in situ for a minimum of 20 min after the end of freezing; the length of time it is left in place has a direct effect on the development of post-operative urethral sloughing. 12 The suprapubic catheter is left on free drainage after the procedure. Clamping of the catheter is normally conducted after 24 h, but it may take several days before the patient has regained normal voiding without residual urine (o50 ml), at which point the catheter is removed; a blockers may be administered for some days perioperatively to facilitate spontaneous voiding.
If a suprapubic catheter is not used, a urethral catheter is inserted and left in place for 1 or 2 weeks. Nonsteroidal anti-inflammatory agents and non-opioid analgesics are used as appropriate and antibiotic prophylaxis is given as recommended in the European Association of Urology guidelines. Follow-up is conducted at week 2, 4 and 6 post-cryotherapy (including urine culture) and PSA is recorded at 3-month intervals up until 18 months and at 6-month intervals thereafter. It is also recommended that sexual function postcryotherapy be maintained through the use of a vacuum device or a phosphodiesterase-5 inhibitor or intracavernous injection.
Discussion
There are special circumstances in which cryotherapy can still be applied as primary therapy outside of the standard situations, but with added precautions. In the case of patients who have already undergone a TURP or open prostatectomy, it is important to place a thermosensor in the urethral sphincter for protection. Placement of the CryoNeedles is more difficult if there is a large TURP defect in the prostatic urethra and only a thin rim of prostate tissue; it is less easy to avoid perforating the urethra and there is added risk of incontinence. Another special patient category is those patients with a large median lobe of the prostate. Although a degree of caution is needed with respect to the position of the urethra (mainly in the bladder neck area), cryotherapy is not contraindicated.
The SeedNet system and regular CryoNeedles can be used for prostates approximately up to and including 50 g. In larger prostates, there might be pelvic bone interference with the placement of the regular CryoNeedles. Hormonal therapy for size reduction might be administered for prostates over 80 g. However, the introduction of the IceRod system with longer and larger freezing zones has allowed larger prostates to be treated without any downsizing or pull-back manoeuvre. The placement of IceRod needles in the prostate differs to that of the regular SeedNet CryoNeedles because of differences in the length and intensity of the ice ball and will be subject of a future technical paper.
A number of series have reported the use of cryotherapy as salvage therapy after radical prostatectomy or radiotherapy. [12] [13] [14] [15] It has been noted that the use of cryosurgery after radiation failure resulted in lower biochemical relapse rates than those achieved with salvage radical prostatectomy after radiation failure. 15 Five-year biochemical relapse-free rates of 55-69% [16] [17] [18] [19] are reported with salvage radical prostatectomy, whereas rates after salvage cryotherapy vary according to the definition used, but are generally lower. 15, 20 Complication rates with salvage cryosurgery have been shown to be higher than with primary cryosurgery, particularly for incontinence rates and pelvic pain. 15 Cryotherapy is also considered to have potential as a palliative therapy in patients with locally advanced cancer, providing pain relief for up to 6 months. 21 In our personal experience, patients failing cryotherapy can undergo a repeat procedure with rarely an increased risk of side effects. Although experience in this area is limited, early results suggest that good outcome can be obtained with a second cryotherapy procedure. The target PSA nadir after cryotherapy is a level of p0.5 ng ml -1 (optimal below detection level), but a level of p1.0 ng ml -1 with stable readings is also considered as acceptable by the group. Published series have defined biochemical recurrence after cryotherapy as an increase in PSA of X0.2 ng ml -1 over the nadir 22 or a level of 0.5 ng ml -1 or 1.0 ng ml -1 . 23 The American Society of Therapeutic Radiology and Oncology ASTRO guidelines have also been used to define failure after cryotherapy, that is three consecutive rises in PSA after the PSA nadir has been reached. 24 In addition, a positive biopsy is required. PSA nadir after cryotherapy is usually seen 3 months after treatment. A Cochrane data base review of the literature was published in 2007 on cryotherapy as a primary therapy in localized prostate cancer. 25 To be included in the review, studies had to have included at least 50 patients with a minimum follow-up of 1 year. The eight case series identified included 1483 patients with a mean pre-operative PSA level of 9.7-39 ng ml -1 . Four of the eight studies did not monitor the temperature of the cryo-procedure and reported a positive biopsy in 17-28% of patients after cryotherapy with a mean PSA nadir of 0.55-1.75 ng ml -1 (median 0.4-1.85 ng ml -1 ). The other four studies used thermocouples to monitor the temperature of the cryo-procedure and reported progression-free survival rates of 71-89% with 1.4-13% of patients having a positive biopsy post-cryotherapy. At 5 years, overall survival was reported as 89-92% in two studies, and disease-specific survival as 94% in one study.
An on-line database of patients treated with whole gland cryotherapy as a primary treatment has published outcome in 1198 patients. 26 Mean (s.d.) pre-treatment PSA was 9.6 (8.6) ng ml -1 . The mean (s.d.) 5-year biochemical disease-free status for the entire population was 77.1% (2.1%) based on the ASTRO criteria and 72.9% (2.1%) base on the newer Phoenix definition (PSA nadir þ 2 ng ml -1 ).
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